KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Receivables (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Receivables for 9 consecutive years, with $106.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 35.09% year-over-year to $106.8 million, compared with a TTM value of $106.8 million through Dec 2025, up 35.09%, and an annual FY2025 reading of $106.8 million, up 35.09% over the prior year.
  • Receivables was $106.8 million for Q4 2025 at Biocryst Pharmaceuticals, up from $91.3 million in the prior quarter.
  • Across five years, Receivables topped out at $106.8 million in Q4 2025 and bottomed at $2.1 million in Q2 2023.
  • Average Receivables over 3 years is $58.4 million, with a median of $64.7 million recorded in 2023.
  • The sharpest move saw Receivables plummeted 92.64% in 2024, then surged 4202.83% in 2025.
  • Year by year, Receivables stood at $57.0 million in 2023, then soared by 38.84% to $79.1 million in 2024, then surged by 35.09% to $106.8 million in 2025.
  • Business Quant data shows Receivables for BCRX at $106.8 million in Q4 2025, $91.3 million in Q3 2025, and $91.2 million in Q2 2025.